Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

·1d ago
Share:PostShare

BILLERICA, Mass. & BEIJING--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market. Initially formed in 2024, the commercialization arrangement combines Quanterix’s ultra-sensitive biomarker de

B

Businesswire

Original source

Read full story

Related Stories

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer